Table 1.
Patient demographics.
| Characteristic | No. of patients (%) | p value | ||
|---|---|---|---|---|
| All patients (N = 255) | Nivolumab (N = 109) | Pembrolizumab (N = 146) | ||
| Median age (range), years | 61 (29–86) | 61 (39–83) | 60 (35–86) | 0.7507 |
| Sex | 0.56 | |||
| Male | 191 (74.90) | 84 (77.06) | 107 (73.29) | |
| Female | 64 (25.10) | 25 (22.94) | 39 (26.71) | |
| ECOG performance status | 0.182 | |||
| 0–1 | 211 (82.75) | 86 (78.90) | 125 (85.62) | |
| ≥ 2 | 44 (17.25) | 23 (21.10) | 21 (14.38) | |
| Smoking history | 0.605 | |||
| Current or former | 157 (61.57) | 65 (59.63) | 92 (63.01) | |
| Never | 98 (38.43) | 44 (40.37) | 54 (36.99) | |
| Stage | 0.126 | |||
| Recurrence | 32 (12.55) | 18 (16.51) | 14 (9.59) | |
| IIIB–IV | 223 (87.45) | 91 (83.49) | 132 (90.41) | |
| Metastasis | ||||
| CNS versus no CNS | 57 (22.35) versus 198 (77.65) | 27 (24.77) versus 82 (75.23) | 30 (20.55) versus 116 (79.45) | 0.45 |
| Intrathoracic only versus no Intrathoracic | 123 (48.24) versus 132 (51.76) | 59 (54.13) versus 50 (45.87) | 64 (43.84) versus 82 (56.16) | 0.128 |
| Histology | 0.148 | |||
| Squamous | 92 (36.08) | 45 (41.28) | 47 (32.19) | |
| Nonsquamous | 163 (63.92) | 64 (58.72) | 99 (67.81) | |
| EGFR mutation status | 0.054 | |||
| Positive | 35 (13.73) | 16 (14.68) | 19 (13.01) | |
| Negative | 136 (53.33) | 49 (44.95) | 87 (59.59) | |
| Not examined | 84 (32.94) | 44 (40.37) | 40 (27.40) | |
| ALK fusion status | 0.177 | |||
| Positive | 4 (1.57) | 3 (2.75) | 1 (0.68) | |
| Negative | 188 (73.73) | 75 (68.81) | 113 (77.40) | |
| Not examined | 63 (24.71) | 31 (28.44) | 32 (21.92) | |
| PD-L1 expression | 0.055 | |||
| < 1 | 15 (5.88) | 6 (5.50) | 9 (6.16) | |
| 1–49 | 30 (11.76) | 12 (11.01) | 18 (12.33) | |
| ≥ 50 | 35 (13.73) | 8 (7.34) | 27 (18.49) | |
| Not examined | 175 (68.63) | 83 (76.15) | 92 (63.01) | |
| Treatment lines | 0.007 | |||
| 1 | 85 (33.33) | 26 (23.85) | 59 (40.41) | |
| ≥ 2 | 170 (66.67) | 83 (76.15) | 87 (59.59) | |
| Combined with chemotherapy | 0.000 | |||
| No | 143 (56.08) | 78 (71.56) | 65 (44.52) | |
| Yes | 112 (43.92) | 31 (28.44) | 81 (55.48) | |
| Cycles of treatment, median (range), No | 5 (1–38) | 6 (1–38) | 5 (1–24) | 0.1123 |
| Follow up time, (range), days | 249 (13–1,288) | 289 (31–1,288) | 230 (28–1,286) | 0.2035 |
| Overall response rate | 87 (34.12) | 25 (22.94) | 62 (42.47) | 0.001 |
ECOG Eastern Cooperative Oncology Group, CNS central nervous system, EGFR epidermal growth factor receptor gene, ALK anaplastic lymphoma kinase gene, PD-L1 programmed cell death ligand 1, No. number.